Berchuck A, Rodriguez G C, Kamel A, Dodge R K, Soper J T, Clarke-Pearson D L, Bast R C
Department of Obstetrics and Gynecology, Duke University, Durham, NC 27710.
Am J Obstet Gynecol. 1991 Feb;164(2):669-74. doi: 10.1016/s0002-9378(11)80044-x.
Previous studies in breast and bladder cancer have suggested that epidermal growth factor receptor is expressed by only a proportion of cancers and is associated with poor clinical outcome. We used a monoclonal antibody specifically reactive with the extracellular domain of the epidermal growth factor receptor to localize this receptor immunohistochemically in frozen sections of normal ovary and epithelial ovarian cancer. Normal ovarian epithelium was found to express epidermal growth factor receptor in all cases. Among 87 ovarian cancers, however, 23% did not express immunohistochemically detectable receptor. Epidermal growth factor receptor expression was not related to histologic grade or stage, but was associated with poor survival (p less than 0.05). The median length of survival of patients with tumors that did not express epidermal growth factor receptor was 40 months compared with 26 months in patients with tumors that did express epidermal growth factor receptor. As in breast and bladder cancer, expression of epidermal growth factor receptor in ovarian cancer appears to be a poor prognostic factor.
先前针对乳腺癌和膀胱癌的研究表明，仅一部分癌症会表达表皮生长因子受体，且其与不良临床预后相关。我们使用了一种与表皮生长因子受体胞外域特异性反应的单克隆抗体，通过免疫组织化学方法在正常卵巢和上皮性卵巢癌的冰冻切片中定位该受体。结果发现，所有病例的正常卵巢上皮均表达表皮生长因子受体。然而，在87例卵巢癌中，23%未表达免疫组织化学可检测到的受体。表皮生长因子受体表达与组织学分级或分期无关，但与生存不良相关（p<0.05）。未表达表皮生长因子受体的肿瘤患者的中位生存期为40个月，而表达表皮生长因子受体的肿瘤患者的中位生存期为26个月。与乳腺癌和膀胱癌一样，卵巢癌中表皮生长因子受体的表达似乎是一个不良预后因素。
